OncoSil Medical Ltd (AU:OSL) has released an update.
OncoSil Medical Ltd has announced the temporary delay in the appointment of Peter Hall as Non-Executive Director to October 1, 2024, due to personal family matters. Hall, who owns about 4% of OncoSil’s issued capital, is committed to actively contributing to the company’s future, especially in enhancing treatments for pancreatic cancer. OncoSil, known for its breakthrough OncoSil™ brachytherapy device, is advancing in both clinical trials and the commercialization of its treatment in over 30 countries.
For further insights into AU:OSL stock, check out TipRanks’ Stock Analysis page.
